Publication:
Verapamil and alzheimer’s disease: past, present, and future

Simple item page
dc.contributor.authorMorales-Delgado, Nicanor
dc.contributor.authorVidal Mena, David
dc.contributor.authorPascual Martínez, María
dc.contributor.authorCaballero Bleda, María
dc.contributor.authorAlonso Fuentes, Antonia
dc.contributor.authorPopovic, Natalija
dc.contributor.authorPopovic Popovic, Miroljub
dc.contributor.departmentAnatomía Humana y Psicobiología
dc.date.accessioned2024-06-18T07:33:25Z
dc.date.available2024-06-18T07:33:25Z
dc.date.issued2020-05-05
dc.description© 2020 Popovic. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0/. This document is the Published version of a Published Work that appeared in final form in Frontiers in Pharmacology. To access the final edited and published work see https://doi.org/10.3389/fphar.2020.00562
dc.description.abstractVerapamil is a phenylalkylamine class calcium channel blocker that for half a century has been used for the treatment of cardiovascular diseases. Nowadays, verapamil is also considered as a drug option for the treatment of several neurological and psychiatric disorders, such as cluster headache, bipolar disorders, epilepsy, and neurodegenerative diseases. Here, we review insights into the potential preventive and therapeutic role of verapamil on Alzheimer’s disease (AD) based on limited experimental and clinical data. Pharmacological studies have shown that verapamil has a wide therapeutic spectrum, including antihypertensive, anti-inflammatory, and antioxidative effects, regulation of the blood-brain barrier function, due to its effect on P-glycoprotein, as well as adjustment of cellular calcium homeostasis, which may result in the delay of AD onset or ameliorate the symptoms of patients. However, the majority of the AD individuals are on polypharmacotherapy, and the interactions between verapamil and other drugs need to be considered. Therefore, for an appropriate and successful AD treatment, a personalized approach is more than necessary. A well-known narrow pharmacological window of verapamil efficacy may hinder this approach. It is therefore important to note that the verapamil efficacy may be conditioned by different factors. The onset, grade, and brain distribution of AD pathological hallmarks, the time-sequential appearances of AD-related cognitive and behavioral dysfunction, the chronobiologic and gender impact on calcium homeostasis and AD pathogenesis may somehow be influencing that success. In the future, such insights will be crucial for testing the validity of verapamil treatment on animal models of AD and clinical approaches.es
dc.formatapplication/pdfes
dc.format.extent10es
dc.identifier.citationFrontiers in Pharmacology, Volume 11(2020), 562
dc.identifier.doihttps://doi.org/10.3389/fphar.2020.00562
dc.identifier.issnElectronic: 1663-9812
dc.identifier.urihttp://hdl.handle.net/10201/142381
dc.languageenges
dc.publisherFrontiers Media
dc.relationSpanish Ministry of Science, Innovation and Universities and European Regional Development Fund (FEDER; PGC2018-098229-B-100).es
dc.relation.publisherversionhttps://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.00562/fulles
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAlzheimer’s diseasees
dc.subjectEmotiones
dc.subjectlearninges
dc.subjectMemoryes
dc.subjectVerapamiles
dc.subject.otherCDU::6 - Ciencias aplicadases
dc.titleVerapamil and alzheimer’s disease: past, present, and futurees
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
relation.isAuthorOfPublicatione6582236-1657-4fd1-8c98-d549ab609b91
relation.isAuthorOfPublicationdc3015b4-805d-4b6e-a49f-f2d73bb3c2b2
relation.isAuthorOfPublication43b53091-f5bf-4b46-b164-88d2a3670e2f
relation.isAuthorOfPublication.latestForDiscoverye6582236-1657-4fd1-8c98-d549ab609b91
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Popovic et al., Front. Pharmacol. 2020.pdf
Size:
559.15 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos